NanoSyrinx announces closure of its Pre-Seed investment round

The team at NanoSyrinx are delighted to announce our pre-seed financing with an excellent board of investors: MVentures, BioCity and UKI2S.

Our seed round is helping us deliver key scientific milestones as we look to create a revolution in the delivery of biologic molecules in the cell and gene therapy and conventional therapeutic space.

NanoSyrinx is now preparing for its next full seed raise Q4-2020/Q1-2021, so if you’d like to be involved in the next round and join us on our journey, please get in touch!

Full press release details can be found here:

Follow us on social media to stay up to date!


Read more news

NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – to discuss the future and potential of Synthetic Biology for the UK and for human health. The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. […]

Read more

NanoSyrinx featured by Spin-up Science on YouTube

Ben Miles at Spin-up Science took time recently to feature NanoSyrinx in their latest YouTube video. Follow the links below to learn how what NanoSyrinx is developing could, in Ben’s words, “change medicine forever”. You can also hear more from the discussion on the Scientist-to-CEO podcast Ben runs, which is available here: Spin up Science […]

Read more

NanoSyrinx named as winner of the 2022 AbbVie UK Golden Ticket programme

NanoSyrinx has been named as the winner of the 2022 AbbVie UK Golden Ticket accelerator programme. The 2022 AbbVie UK Golden Ticket is a competitive award, open to early-stage life sciences companies and biotech start-ups that are working to develop cutting-edge therapies or technology platforms. Under the programme, the company will benefit from: One year […]

Read more